Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Feb 2008

Marks Jenifer L, Broderick Stephen, Zhou Qin, Chitale Dhananjay, Li Allan R, Zakowski Maureen F, Kris Mark G, Rusch Valerie W, Azzoli Christopher G, Seshan Venkatraman E, Ladanyi Marc, Pao William

Abstract excerpt

BACKGROUND: Somatic mutations in EGFR (exons 19 and 21) and KRAS (exon 2) are found in lung adenocarcinomas and have potential prognostic value in patients with advanced disease. These mutations also have therapeutic significance, as they predict for sensitivity and resistance, respectively, to EGFR tyrosine kinase inhibitor therapy. Whether EGFR and KRAS mutations also have an impact on survival in patients who...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Genes, ras

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Share to Survival Analysis

Source

Identifiers

PMID: 18303429
DOI: 10.1097/JTO.0b013e318160c607

Genes

EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma.PMID 18303429Read ↗

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcome in resected non-small cell lung cancer patients.Semantic proximity Read ↗

EGFR and KRAS mutations in patients with adenocarcinoma of the lung.Semantic proximity Read ↗

KRAS mutation: should we test for it, and does it matter?Semantic proximity Read ↗

KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma.Semantic proximity Read ↗

Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.Semantic proximity Read ↗

Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: report on initial experience and clinical utility at a single center.Semantic proximity Read ↗

Clinical features reflect exon sites of EGFR mutations in patients with resected non-small-cell lung cancer.Semantic proximity Read ↗

Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma.Semantic proximity Read ↗

EGFR and KRAS Mutations in Patients With Adenocarcinoma of the LungSemantic proximity Read ↗

Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications.Semantic proximity Read ↗

Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review.Semantic proximity Read ↗

KRAS mutations in lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.